Cyclic HIV protease inhibitors:: Design and synthesis of orally bioavailable, pyrazole P2/P2′ cyclic ureas with improved potency

被引：68

作者：

Han, Q ^{[1
]}

Chang, CH ^{[1
]}

Li, RH ^{[1
]}

Ru, Y ^{[1
]}

Jadhav, PK ^{[1
]}

Lam, PYS ^{[1
]}

机构：

[1] Dupont Merck Pharmaceut Co, Expt Stn, Wilmington, DE 19880 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 1998年 / 41卷 / 12期

关键词：

D O I：

10.1021/jm9704199

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Highly potent HIV-1 protease (HIVPR) inhibitors have been designed and synthesized by introducing bidentate hydrogen-bonding oxime and pyrazole groups at the mete-position of the phenyl ring on the P2/P2' substituents of cyclic ureas. Nonsymmetrical cyclic ureas incorporating 3(1H)-pyrazolylbenzyl as P2 and hydrophilic functionalities as P2' show potent protease inhibition and antiviral activities against HIV and have good oral bioavailabilities. The X-ray structure of HTVPR.10A complex confirms that the two pyrazole rings of 10A form bidentate hydrogen bonds with the side-chain oxygen (C=O) and backbone nitrogen (N-H) of Asp30/30' of HIVPR.

引用

页码：2019 / 2028

页数：10

共 33 条

[11] RAPID TURNOVER OF PLASMA VIRIONS AND CD4 LYMPHOCYTES IN HIV-1 INFECTION [J].

HO, DD ;

NEUMANN, AU ;

PERELSON, AS ;

CHEN, W ;

LEONARD, JM ;

MARKOWITZ, M .

NATURE, 1995, 373 (6510) :123-126

[12] Improved cyclic urea inhibitors of the HIV-I protease: Synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450 [J].

Hodge, CN ;

Aldrich, PE ;

Bacheler, LT ;

Chang, CH ;

Eyermann, CJ ;

Garber, S ;

Grubb, M ;

Jackson, DA ;

Jadhav, PK ;

Korant, B ;

Lam, PYS ;

Maurin, MB ;

Meek, JL ;

Otto, MJ ;

Rayner, MM ;

Reid, C ;

Sharpe, TR ;

Shum, L ;

Winslow, DL ;

EricksonViitanen, S .

CHEMISTRY & BIOLOGY, 1996, 3 (04) :301-314

[13] CHARACTERIZATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 MUTANTS WITH DECREASED SENSITIVITY TO PROTEINASE-INHIBITOR RO-31-8959 [J].

JACOBSEN, H ;

YASARGIL, K ;

WINSLOW, DL ;

CRAIG, JC ;

KROHN, A ;

DUNCAN, IB ;

MOUS, J .

VIROLOGY, 1995, 206 (01) :527-534

[14]

KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025

[15]

KEMF DJ, 1996, CURR PHARM DESIGN, V2, P225

[16] ABT-538 IS A POTENT INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE AND HAS HIGH ORAL BIOAVAILABILITY IN HUMANS [J].

KEMPF, DJ ;

MARSH, KC ;

DENISSEN, JF ;

MCDONALD, E ;

VASAVANONDA, S ;

FLENTGE, CA ;

GREEN, BE ;

FINO, L ;

PARK, CH ;

KONG, XP ;

WIDEBURG, NE ;

SALDIVAR, A ;

RUIZ, L ;

KATI, WM ;

SHAM, HL ;

ROBINS, T ;

STEWART, KD ;

HSU, A ;

PLATTNER, JJ ;

LEONARD, JM ;

NORBECK, DW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (07) :2484-2488

[17] New series of potent, orally bioavailable, non-peptidic cyclic sulfones as HIV-1 protease inhibitors [J].

Kim, CU ;

McGee, LR ;

Krawczyk, SH ;

Harwood, E ;

Harada, Y ;

Swaminathan, S ;

Bischofberger, N ;

Chen, MS ;

Cherrington, JM ;

Xiong, SF ;

Griffin, L ;

Cundy, KC ;

Lee, A ;

Yu, B ;

Gulnik, S ;

Erickson, JW .

JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (18) :3431-3434

[18] CRYSTAL-STRUCTURE OF HIV-1 PROTEASE IN COMPLEX WITH VX-478, A POTENT AND ORALLY BIOAVAILABLE INHIBITOR OF THE ENZYME [J].

KIM, EE ;

BAKER, CT ;

DWYER, MD ;

MURCKO, MA ;

RAO, BG ;

TUNG, RD ;

NAVIA, MA .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1995, 117 (03) :1181-1182

[19] SAFETY AND ACTIVITY OF SAQUINAVIR IN HIV-INFECTION [J].

KITCHEN, VS ;

SKINNER, C ;

ARIYOSHI, K ;

LANE, EA ;

DUNCAN, IB ;

BURCKHARDT, J ;

BURGER, HU ;

BRAGMAN, K ;

PINCHING, AJ ;

WEBER, JN .

LANCET, 1995, 345 (8955) :952-955

[20] ACTIVE HUMAN IMMUNODEFICIENCY VIRUS PROTEASE IS REQUIRED FOR VIRAL INFECTIVITY [J].

KOHL, NE ;

EMINI, EA ;

SCHLEIF, WA ;

DAVIS, LJ ;

HEIMBACH, JC ;

DIXON, RAF ;

SCOLNICK, EM ;

SIGAL, IS .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) :4686-4690

← 1 2 3 4 →